keyword
MENU ▼
Read by QxMD icon Read
search

Rilpivirine

keyword
https://www.readbyqxmd.com/read/29775399/dolutegravir-and-rilpivirine-for-the-maintenance-treatment-of-virologically-suppressed-hiv-1-infection
#1
Jose L Casado, Marta Monsalvo, Aurora M Rojo, María Fontecha, Miguel A Rodriguez-Sagrado
Triple combinations of antiretroviral (ART) drugs are the standard treatment for HIV infection, but the challenges include long-term side effects, high costs, and adherence. The recent advent of potent and well tolerated ART has renewed the interest for newer ART strategies. A dual regimen with the combination of dolutegravir (DTG) and rilpivirine (RPV), two well tolerated, metabolic-friendly, and potent drugs could offer additional benefits. Areas covered: A review of recent randomized trials and observational cohorts concerning the use of a dual therapy with DTG plus RPV as a switching strategy in patients with viral suppression...
May 18, 2018: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/29746267/cabotegravir-its-potential-for-antiretroviral-therapy-and-preexposure-prophylaxis
#2
Hans-Jürgen Stellbrink, Christian Hoffmann
PURPOSE OF REVIEW: Analyzing the evidence for the strand transfer integrase inhibitor cabotegravir (CAB; GSK744, GSK1265744), its properties and differences from other compounds in the class, as well as reviewing the preclinical and clinical evidence for its potential in antretroviral therapy and medical HIV prevention. RECENT FINDINGS: CAB has been investigated both as an oral and an injectable compound. Recent results show that it has promising properties with regards to its potential for parenteral maintenance therapy in combination with other compounds in HIV-infected patients currently suppressed on oral agents, as well as in preexposure prophylaxis...
May 8, 2018: Current Opinion in HIV and AIDS
https://www.readbyqxmd.com/read/29732907/prevalence-of-rilpivirine-and-etravirine-resistance-mutations-in-hiv-1-subtype-c-infected-patients-failing-nevirapine-or-efavirenz-based-combination-antiretroviral-therapy-in-botswana
#3
Thabo Diphoko, Simani Gaseitsiwe, Ishmael Kasvosve, Sikhulile Moyo, Harriet Okatch, Rosemary Musonda, Mark A Wainberg, Joseph Makhema, Richard Marlink, Vladimir Novitsky, M Essex
BACKGROUND: Rilpivirine (RPV) and Etravirine (ETR) are approved second-generation non-nucleoside reverse transcriptase inhibitors (NNRTI) for HIV treatment. There is a cross-resistance HIV mutation profile between first- and second-generation NNRTI drugs. We determined the prevalence of HIV-1drug-resistance mutations (DRM) to RPV and ETR in Botswana. METHODS: A total of 168 HIV-1 polymerase gene sequences from participants failing nevirapine or efavirenz-containing regimens were analysed for drug resistance mutations using the Stanford University HIV drug resistance database...
May 6, 2018: AIDS Research and Human Retroviruses
https://www.readbyqxmd.com/read/29731650/durability-safety-and-efficacy-of-rilpivirine-in-clinical-practice-results-from-the-scolta-project
#4
Paola Bagella, Giuseppe Vl De Socio, Elena Ricci, Barbara Menzaghi, Canio Martinelli, Nicola Squillace, Paolo Maggi, Giancarlo Orofino, Leonardo Calza, Laura Carenzi, Benedetto Maurizio Celesia, Giovanni Penco, Antonio Di Biagio, Laura Valsecchi, Francesca Vichi, Valeria Colombo, Giustino Parruti, Chiara Dentone, Katia Falasca, Paolo Bonfanti, Giordano Madeddu
Rilpivirine is associated with a good efficacy and safety profile. However, data from real-life settings are scarce. Methods: We investigated the durability, safety and efficacy of Rilpivirine-based antiretroviral therapy in a prospective, observational, multicenter study. Results: We enrolled 499 HIV-infected patients, 360 (72.1%) males, mean age 43.4 ± 10.5 years, mean CD4 600 ± 327 cell/μL, mean HIV-RNA 3.80 ± 1.15 log10 cp/mL. After a median follow up of 16 months, 81 (16...
2018: Infection and Drug Resistance
https://www.readbyqxmd.com/read/29726595/development-and-validation-of-an-hplc-uv-method-for-quantification-of-elvitegravir-and-others-new-antiretrovirals-dolutegravir-and-rilpivirine-in-the-plasma-of-hiv-positive-patients
#5
Massimo Tempestilli, Adriana Ammassari, Antonio D'Avolio, Stefania Cicalini, Anna Loredana Gallo, Simone Fazio, Andrea Antinori, Leopoldo P Pucillo
Therapeutic drug monitoring may be crucial in selected clinical conditions for the management of HIV infection. In the last years, new antiretrovirals have been introduced and in particular elvitegravir (EVG) is now recommended for first-line and in simplification treatment as well as dolutegravir (DTG) and rilpivirine (RPV). The aim of this study was to develop and validate a High Performance Liquid Chromatography-Ultra Violet (HPLC-UV) method for determining EVG and others newest antiretrovirals DTG and RPV in human plasma...
May 4, 2018: Biomedical Chromatography: BMC
https://www.readbyqxmd.com/read/29700852/lc-ms-ms-method-for-the-simultaneous-determination-of-tenofovir-emtricitabine-elvitegravir-and-rilpivirine-in-dried-blood-spots
#6
Pavan Kumar Prathipati, Subhra Mandal, Christopher J Destache
A simple, short, and rugged LC-MS/MS method for the simultaneous determination of tenofovir, emtricitabine, elvitegravir and rilpivirine was developed and validated. Dried blood spots were prepared with 25 μL of spiked whole blood. A 3 mm punch was extracted with methanol containing labeled internal standards. Ten microliter was injected into LC-MS/MS using isocratic mobile phase composed of 0.1% formic acid in water and 0.1% formic acid in acetonitrile (45: 55 v/v) at a flow rate of 0.25 mL/min. The method was validated in the range of 10 to 2000 ng/mL for all four analytes...
April 26, 2018: Biomedical Chromatography: BMC
https://www.readbyqxmd.com/read/29676935/current-and-emerging-two-drug-approaches-for-hiv-1-therapy-in-art-na%C3%A3-ve-and-art-experienced-virologically-suppressed-patients
#7
Barbara Rossetti, Francesca Montagnani, Andrea De Luca
Current guidelines recommend a 2-drug antiretroviral regimen as an alternative to triple antiretroviral therapy (ART) in selected patients to reduce long-term toxicity and costs. Areas covered: This review is intended to provide insight into the efficacy, safety and tolerability of 2-drug versus 3-drug ART in naïve and in treatment-experienced virologically-suppressed patients. Expert opinion: Dual therapy regimens are not feasible in HBV-coinfected individuals and should not be applied during pregnancy. Positive data on 2-drug ART in drug naïve patients are still limited, while, in virologically-suppressed individuals, several regimens have shown non-inferiority as compared to 3-drug regimens...
May 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29649076/pharmacokinetics-of-tenofovir-alafenamide-when-co-administered-with-other-hiv-antiretrovirals
#8
Rebecca Begley, Moupali Das, Lijie Zhong, John Ling, Brian P Kearney, Joseph M Custodio
BACKGROUND: Tenofovir alafenamide (TAF), a prodrug of the nucleotide analogue tenofovir (TFV), is an antiretroviral (ARV) agent approved either as a complete regimen (elvitegravir/cobicistat/emtricitabine (F)/tenofovir alafenamide (TAF), rilpivirine/F/TAF, bictegravir/F/TAF), or for use with other ARVs (F/TAF), for treatment of HIV. TAF is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) transporters. Disposition of TAF may be altered by co-medications that can inhibit or induce P-gp or BCRP transporters...
April 10, 2018: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/29623097/renal-effects-of-non-tenofovir-antiretroviral-therapy-in-patients-living-with-hiv
#9
REVIEW
Milena M McLaughlin, Aimee J Guerrero, Andrew Merker
A review of literature published regarding non-tenofovir antiretroviral agents causing renal adverse effects was conducted. The literature involving renal adverse effects and antiretroviral therapy is most robust with protease inhibitors, specifically atazanavir and indinavir, and includes reports of crystalluria, leukocyturia, nephritis, nephrolithiasis, nephropathy and urolithiasis. Several case reports describe potential nephropathy (including Fanconi syndrome) secondary to administration of abacavir, didanosine, lamivudine and stavudine...
2018: Drugs in Context
https://www.readbyqxmd.com/read/29607652/stable-caloric-intake-and-continued-virologic-suppression-for-hiv-positive-antiretroviral-treatment-experienced-women-after-switching-to-a-single-tablet-regimen-of-emtricitabine-rilpivirine-and-tenofovir-disoproxil-fumarate
#10
Prema Menezes, Katie Mollan, Erin Hoffman, Zimeng Xie, Jennifer Wills, Cheryl Marcus, John Rublein, Michael Hudgens, Joseph J Eron
BACKGROUND: Benefits of switching to a single-tablet regimen (STR) of FTC/RPV/TDF in virologically suppressed antiretroviral treatment experienced HIV-positive women include pregnancy category B rating and lack of clinically significant drug interactions between RPV and oral contraceptives. Unfortunately, studies involving switching to FTC/RPV/TDF enrolled fewer than 25% women. We undertook this 48 week study to assess the ability of virologically suppressed HIV-positive women switching to RPV STR to remain virologically suppressed and comply with the caloric intake requirement...
April 1, 2018: AIDS Research and Human Retroviruses
https://www.readbyqxmd.com/read/29595351/treatment-and-prevention-of-hiv-infection-with-long-acting-antiretrovirals
#11
Laura Benítez-Gutiérrez, Vicente Soriano, Silvia Requena, Ana Arias, Pablo Barreiro, Carmen de Mendoza
Current antiretroviral therapy allows to achieve and sustain maximal suppression of HIV replication in most treated patients. As result, the life expectancy of HIV-infected persons has improved dramatically and is nowadays similar to that of the HIV-negative population. However, oral antiretrovirals have to be taken daily and indefinitely to avoid resumption of HIV replication and selection of drug resistance. Unfortunately, drug adherence is often suboptimal and tends to decline over time. Areas covered: New drugs, formulations and delivery systems are being developed for extended-release of antiretrovirals...
May 2018: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/29566538/frequent-cross-resistance-to-rilpivirine-among-subtype-c-hiv-1-from-first-line-antiretroviral-therapy-failures-in-south-africa
#12
Kerri J Penrose, Chanson J Brumme, Maritsa Scoulos-Hanson, Kristen Hamanishi, Kelley Gordon, Raquel V Viana, Carole L Wallis, P Richard Harrigan, John W Mellors, Urvi M Parikh
Background Rilpivirine (TMC278LA) is a promising drug for pre-exposure prophylaxis of HIV-1 because of its sub-nanomolar potency and long-acting formulation; however, increasing transmission of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 with potential cross-resistance to rilpivirine could reduce its preventive efficacy. This study investigated rilpivirine cross-resistance among recombinant subtype C HIV-1 derived from 100 individuals failing on first-line non-nucleoside reverse transcriptase inhibitor-containing antiretroviral therapy in South Africa whose samples were sent for routine HIV-1 drug resistance testing to Lancet Laboratories (Johannesburg, South Africa)...
January 2018: Antiviral Chemistry & Chemotherapy
https://www.readbyqxmd.com/read/29553948/dolutegravir-rilpivirine-coformulation
#13
Hsin-Yun Sun, Sui-Yuan Chang, Chien-Ching Hung
PURPOSE OF REVIEW: With prolonged life expectancy in HIV-positive patients on combination antiretroviral therapy, the quest for reducing lifelong drug exposure and minimizing or avoiding the toxicities of combination antiretroviral therapy while maintaining viral suppression has emerged when coformulations of antiretroviral agents with improved convenience, and better tolerability and efficacy became available. This review aims to update the current experience with the novel two-drug combination of dolutegravir (DTG) and rilpivirine (RPV) and elucidate the possible applications and limitations of coformulated DTG-RPV in the future...
March 16, 2018: Current Opinion in HIV and AIDS
https://www.readbyqxmd.com/read/29550449/hiv-care-in-central-and-eastern-europe-how-close-are-we-to-the-target
#14
Deniz Gokengin, Cristiana Oprea, Josip Begovac, Andrzej Horban, Arzu Nazlı Zeka, Dalibor Sedlacek, Bayjanov Allabergan, Esmira A Almamedova, Tatevik Balayan, Denes Banhegyi, Pavlina Bukovinova, Nikoloz Chkhartishvili, Alymbaeva Damira, Edona Deva, Ivaylo Elenkov, Luljeta Gashi, Dafina Gexha-Bunjaku, Vesna Hadciosmanovic, Arjan Harxhi, Tiberiu Holban, Djorje Jevtovic, David Jilich, Justyna Kowalska, Djhamal Kuvatova, Natalya Ladnaia, Adkhamjon Mamatkulov, Aleksandra Marjanovic, Maria Nikolova, Mario Poljak, Kristi Rüütel, Azzaden Shunnar, Milena Stevanovic, Zhanna Trumova, Oleg Yurin
OBJECTIVES: The aim of this survey was to describe the current status of HIV care in Central and Eastern European countries and to look at how close the region is to achieve the UNAIDS 2020 target of 90-90-90. METHODS: In 2014 data were collected from 24 Central and Eastern European countries by a 38-item questionnaire. RESULTS: All countries reported mandatory screening of blood and organ donors for HIV. Other groups who were subjected to targeted screening were people who inject drugs (PWID) (15/24; 62...
March 14, 2018: International Journal of Infectious Diseases: IJID
https://www.readbyqxmd.com/read/29529910/safety-and-efficacy-of-dolutegravir-plus-rilpivirine-in-treatment-experienced-hiv-infected-patients-the-dorivir-study
#15
Rosario Palacios, M Mayorga, C M González-Domenech, C Hidalgo-Tenorio, C Gálvez, L Muñoz-Medina, J de la Torre, A Lozano, M Castaño, M Omar, Jesús Santos
OBJECTIVES: To analyze the efficacy and safety of dolutegravir/rilpivirine (DTG/RPV) in HIV-infected patients who switched from any other antiretroviral therapy (ART). METHODS: Open-label, multicenter study including patients who switched to DTG/RPV between February 2015 and February 2016. Efficacy (HIV RNA <50 copies/mL), adverse events, and metabolic changes at 24 weeks were analyzed. RESULTS: A total of 104 participants were included, who switched for the following reasons: toxicity/intolerance (42...
January 2018: Journal of the International Association of Providers of AIDS Care
https://www.readbyqxmd.com/read/29528944/rilpivirine-plasma-and-cervico-vaginal-concentrations-in-women-during-pregnancy-and-postpartum
#16
Ahizechukwu C Eke, Nahida Chakhtoura, Angela Kashuba, Brookie M Best, Craig Sykes, Jiajia Wang, Alice M Stek, Elizabeth Smith, Samantha Calabrese, Edmund V Capparelli, Mark Mirochnick
BACKGROUND: Concentrations of antiretrovirals (ARVs) in the genital tract play a key role in pre-exposure prophylaxis. This study aims to describe rilpivirine (Edurant) concentrations in the genital tract in pregnant and postpartum women. METHODS: International Maternal Pediatric Adolescent AIDS Clinical Trials Protocol P1026s is an ongoing, prospective study of antiretroviral pharmacokinetics (PK) in HIV infected pregnant women that include a cohort receiving rilpivirine combination regimen...
March 8, 2018: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/29522076/drug-drug-interactions-studies-between-hcv-antivirals-sofosbuvir-velpatasvir-and-boosted-and-unboosted-hiv-antiretroviral-regimens-in-healthy-volunteers
#17
Erik Mogalian, Luisa M Stamm, Anu Osinusi, Diana M Brainard, Gong Shen, Kah Hiing John Ling, Anita Mathias
Background: Combining antiviral regimens in the HCV/HIV coinfected population can be complex as they share overlapping mechanisms for elimination that may result in potential drug interactions. The pharmacokinetics, safety, and tolerability of concomitantly administered sofosbuvir/velpatasvir (SOF/VEL) with multiple commonly prescribed antiretroviral (ARV) regimens were evaluated. Methods: Healthy volunteers were enrolled into two phase 1, open-label, randomized, multiple-dose, cross-over studies...
March 7, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29493093/highlights-of-the-2017-european-aids-clinical-society-eacs-guidelines-for-the-treatment-of-adult-hiv-positive-persons-version-9-0
#18
L Ryom, C Boesecke, M Bracchi, J Ambrosioni, A Pozniak, J Arribas, G Behrens, Pgm Mallon, M Puoti, A Rauch, J M Miro, O Kirk, C Marzolini, J D Lundgren, M Battegay
BACKGROUND: The European AIDS Clinical Society (EACS) Guidelines have since 2005 provided multidisciplinary recommendations for the care of HIV-positive persons in geographically diverse areas. GUIDELINE HIGHLIGHTS: Major revisions have been made in all sections of the 2017 Guidelines: antiretroviral treatment (ART), comorbidities, coinfections and opportunistic diseases. Newly added are also a summary of the main changes made, and direct video links to the EACS online course on HIV Management...
May 2018: HIV Medicine
https://www.readbyqxmd.com/read/29492905/tenofovir-associated-bone-adverse-outcomes-among-a-us-national-historical-cohort-of-hiv-infected-veterans-risk-modification-by-concomitant-antiretrovirals
#19
Joanne LaFleur, Adam P Bress, Joel Myers, Lisa Rosenblatt, Jacob Crook, Kristin Knippenberg, Roger Bedimo, Pablo Tebas, Heather Nyman, Stephen Esker
INTRODUCTION: Tenofovir disoproxil fumarate (TDF) has been associated with greater incidences of bone complications, which might be modified by some concomitantly administered antiretrovirals, possibly by their effect on tenofovir concentrations. We compared bone adverse outcomes among treatment-naïve HIV-infected US veterans initiating efavirenz (EFV)-containing TDF/emtricitabine (FTC) regimens versus those initiating non-EFV-containing TDF/FTC regimens. METHODS: Using national Veterans Health Administration clinical and administrative data sets, we identified a cohort of treatment-naïve HIV-infected veterans without bone disease who initiated therapy with TDF/FTC plus EFV, rilpivirine, elvitegravir/cobicistat, or ritonavir-boosted protease inhibitors in 2003-2015...
February 28, 2018: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/29482352/dolutegravir-plus-rilpivirine-as-a-switch-option-in-cart-experienced-patients-96-week-data
#20
Amedeo Ferdinando Capetti, Maria Vittoria Cossu, Gaetana Sterrantino, Giorgio Barbarini, Simona Di Giambenedetto, Giuseppe Vittorio De Socio, GianCarlo Orofino, Antonio Di Biagio, Benedetto M Celesia, Stefano Rusconi, Barbara Argenteri, Giuliano Rizzardini
BACKGROUND: Data from clinical studies confirm the efficacy of switching to dolutegravir (DTG) plus rilpivirine (RPV) in selected patients. OBJECTIVE: The primary objective is to report the 96-week virological suppression in our cohort, assessing the durability of this strategy in complicated situations. The secondary objective is to describe the safety and metabolic profile. METHODS: All patients who had switched to DTG plus RPV between October 1, 2014, and September 30, 2015, were analyzed using a retrospective-prospective design, approved by ethics committees...
February 1, 2018: Annals of Pharmacotherapy
keyword
keyword
14741
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"